{
  "catalysts": [
    {
      "ticker": "VNDA",
      "current_price": 8.82,
      "market_cap": "$556M",
      "conviction_score": 9,
      "thesis": "FDA approval of NEREUS (tradipitant) marks the first pharmacologic innovation for motion sickness in 40 years, targeting a massive unmet need with a launch in early 2026. Micro-cap valuation ($556M) leaves significant room for repricing as commercial roll-out begins.",
      "catalyst_details": "FDA approved NEREUS (tradipitant) for the prevention of motion sickness on December 30, 2025. This was a PDUFA event with a positive outcome.",
      "absorption_status": "Initial reaction (+25% on Dec 31) reflects approval, but the 'first-in-40-years' narrative typically drives multi-week Post-Earnings Announcement Drift (PEAD).",
      "earnings_date": "2026-02-18",
      "relative_volume": "9.7x (Dec 31)",
      "stop_loss_trigger": "$7.96 (Trailing 1.5 ATR)",
      "sentiment": "Bullish",
      "prediction_market": "N/A",
      "recency_proof": "Dec 30, 2025 FDA Approval Announcement",
      "risk": "Commercial execution and launch trajectory.",
      "expected_upside": "35-50% | Target: $10.54 (3.0 ATR)",
      "mispricing_evidence": "Stock trades at ~1x peak sales potential of a novel mass-market drug; historical comps for first-in-class approvals suggest valuation expansion.",
      "x_sentiment": "High retail interest following approval.",
      "atr_value": 0.57,
      "target_price": 10.54
    },
    {
      "ticker": "AXSM",
      "current_price": 182.64,
      "market_cap": "$8.5B",
      "conviction_score": 8,
      "thesis": "FDA Priority Review designation for AXS-05 in Alzheimer's Agitation accelerates the PDUFA timeline to April 2026, significantly de-risking the regulatory path for a blockbuster indication.",
      "catalyst_details": "On Dec 31, 2025, FDA accepted the NDA for AXS-12 (Narcolepsy) and sNDA for AXS-05 (Alzheimer's Agitation) with Priority Review. PDUFA set for April 30, 2026.",
      "absorption_status": "Stock surged 20% on Dec 31; however, the dual-NDA acceptance and Priority Review status justify a sustained re-rating above previous resistance levels.",
      "earnings_date": "2026-02-24",
      "relative_volume": "High (Dec 31)",
      "stop_loss_trigger": "$173.20 (Trailing 1.5 ATR)",
      "sentiment": "Bullish",
      "prediction_market": "High confidence in approval",
      "recency_proof": "Dec 31, 2025 FDA Acceptance Press Release",
      "risk": "Regulatory setback in April 2026.",
      "expected_upside": "20-30% | Target: $201.52 (3.0 ATR)",
      "mispricing_evidence": "Priority Review significantly increases probability of approval (PoS), warranting a higher premium than standard review pricing.",
      "x_sentiment": "Very Bullish",
      "atr_value": 6.29,
      "target_price": 201.52
    }
  ]
}